New Phase III data found that investigational linagliptin therapy resulted in significant reductions in blood sugar as measured by hemoglobin A1c (HbA1c) when compared to placebo, both when added to sulfonylurea (SU) in inadequately controlled type 2 diabetes (T2D) patients, and when administered as monotherapy in T2D patients for whom ...

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases).

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that data from a recent clinical trial of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), will be presented at the 46th Annual Meeting of ...

CLEVELAND , June 2 /- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its attendance at the Drug Information Association's 46th Annual Meeting, Facilitating Innovation for Better Health Outcomes , which will be ...

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association ...

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that more than 70 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. "Bayer and Onyx are encouraged by the number and breadth ...

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 ...

EMERYVILLE, Calif. , May 20 /- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL. ...

WAYNE, N.J. and EMERYVILLE, Calif. , May 20 /- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that more than 70 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 2010 American Society of Clinical Oncology ...

In releasing a new report on maternal health nationwide, Amnesty International today revealed that flaws and shocking disparities in maternal health care that the government is ignoring lead to two to three women dying daily in the United States from pregnancy-related complications, with half of these deaths believed preventable, according ...